The effect of prednisolone (20-30 mg daily for six to nine weeks) was studied in eight patients with Crohn's disease and recurrent, preanastomotic ileal inflammation, in respect of symptoms, endoscopic findings and phospholipase A2 activity in the ileal mucosa. The HarveyBradshaw Crohn's disease activity index improved significantly, mainly because of reduced frequency of loose stools and diminution ofabdominal pain. Endoscopy revealed no corresponding decrease in ileal inflammation, which in all cases persisted after treatment. The phospholipase A2 activity in the ileal mucosa was not altered by prednisolone. In two of three patients with concomitant colitits colonic inflammation improved. The study confirmed earlier reports of good symptomatic relieffrom glucocorticoid treatment in Crohn's disease of the small bowel, but endoscopy suggests that this improvement was not the result of resolution of smali intestinal mucosal inflammation.
Although Crohn's disease has been recognised for about 50 years, its aetiology remains obscure and the inflammation inducing mechanisms are poorly understood. Phospholipase A2 is implicated as a major contributor to inflammatory processes,' and has attracted much attention because of its ability to produce substrate for the generation of various inflammatory lipid mediators. Raised intestinal contents of prostaglandins and leucotrienes have been reported in Crohn's disease. 23 In line with these findings, we reported increased activity of phospholipase A2 in the ileal mucosa of patients with ileocaecal Crohn's disease, suggesting a role for this enzyme in the development of the inflammatory process.45 Glucocorticoids are considered to be inhibitors of phospholipase A2 activity and are among the few drugs with documented effect on Crohn's disease of the small intestine. 67 Glucocorticoid (prednisolone) medication was begun with 30 mg daily for two weeks, followed by 25 mg/day for two weeks, and thereafter 20 mg/day. After six to nine weeks, while still on treatment, the patients were re-examined.
PHOSPHOLIPASE A2 ANALYSIS
The biopsy specimens were frozen at -70°C until analysis. They were then thawed, weighed, and disintegrated in a Dounce homogeniser, using 0a 15 (Table III) . In all the patients without generalised colitis-proctitis, the anastomotic recurrence was located on the ileal side of the anastomosis. Ulcers rarely bridge the mucosal join over to the colonic side. Erythema was strictly confined to the ileal side of the anastomosis.
Post treatment endoscopy showed improvement of the inflammatory state of the ileum in two patients (disappearance of erythema or aphthous ulcers). At the anastomosis the inflammation generally was more pronounced with ulcers in seven cases and stricture in four. In one case a tight stricture widened to more than 4 mm (diminution of ulcers) and another deteriorated from more to less than 4 mm (diminution ofulcer but narrowing of the anastomosis, probably cicatricial). Slight endoscopic improvement of anastomotic inflammation -reduction of ulcer size and of oedema -was observed in five other patients, but was insufficient to change the classification according to ulcer size. In two patients whose first endoscopy showed extensive coloproctitis there was complete healing after prednisolone treatment.
No correlation was found between presence of abdominal pain and anastomotic stricture or between relief of pain and regression of such stricture. Five of the seven patients with abdominal pain reported improvement after prednisolone treatment. Three of the five had no stricture and two had unchanged stricture. Of the two patients with unchanged abdominal pain, one had reduction of stricture.
The mucosal phospholipase A2 activity in the neoterminal ileum was almost unchanged after prednisolone treatment (Table II) .
Discussion
As in previous investigations, glucocorticoid treatment greatly improved the patients' symptoms, mainly the diarrhoea and abdominal pain (Table II) . This improvement was accompanied by only a minor reduction ofileal and anastomotic mucosal inflammation, and all patients still had inflammation of the small bowel at the end of the treatment period. The lack of correlation between endoscopic findings and lessening of diarrhoea after treatment implies that mucosal inflammation of the small bowel was not the only cause of the diarrhoea. It cannot be excluded, however, that improvement of minor inflammation of the small bowel, proximal to the part available for endoscopy, was responsible for amelioration of the diarrhoea, and in two cases with reduction of colitis, colonic inflammation probably contributed to the diarrhoea. Increased intestinal synthesis of prostaglandins has previously been reported to accompany intestinal inflammation," 1920 and can cause secretory diarrhoea by impairment of water absorption and secretion of mucus.2' Reduction of diarrhoea might therefore result from glucocorticoid induced impairment of prostaglandin synthesis, also previously observed in inflammatory bowel disease." 19 20 Abdominal pain in some patients with Crohn's disease of the small intestine is undoubtedly caused by partial obstruction arising from stenosis. In our patients, however, correlation was not found between abdominal pain and presence of anastomotic stricture or between relief of pain and regression of stricture. Inflammation in Crohn's disease is often transmural,'6 but only changes of the superficial mucosa are seen at endoscopy. Possibly intestinal inflammation causes pain when it reaches the serosal surface, and the beneficial action of corticosteroid treatment on abdominal pain might be explained by reduction of such transmural inflammation.
In the two patients who had extensive coloproctitis before prednisolone treatment the colorectal mucosa healed, but the anastomotic and ileal inflammation remained unchanged. Thus prednisolone seemed to be more effective against inflammation in the large than in the small gut.
The treatment period before reinvestigation was only six to nine weeks in our cases, and it is not unlikely that more extensive healing would have been found after longer medication. Moreover, it cannot be excluded that healing starts in areas of the gut that are too proximal or too deep in the intestinal wall for endoscopic visualisation.
The mucosal phospholipase A2 activity in the neoterminal ileum was not inhibited by glucocorticoid medication. The implications of this observation are not clear. The unaffected phospholipase A2 activity in biopsy specimens of superficial ileal mucosa accorded with substantially unchanged inflammation at endoscopic viewing. It seems noteworthy that our patients had chronic inflammation and were receiving longterm prednisolone, whereas experimental studies showing induction of phospholipase inhibition by glucocorticoids were short term and performed on non-human tissues.8912 Moreover recent investigations have questioned the mechanism by which glucocorticoids inhibits phospholipase A2 activity,22 23 and our data further question the phospholipase A2 inhibitory effect by glucocorticoids.
Our study thus confirmed the excellent effect of glucocorticoids on symptoms of Crohn's disease of the small intestine but this, remarkably, was not accompanied by a significant diminution of endoscopically observed small intestinal inflammation. These findings suggest that at least some of the symptoms in small bowel Crohn's disease are not caused by the mucosal endoscopically visualised inflammation, but by other, concomitant factors. 
